首页> 中文期刊> 《中国医药导报》 >肠道菌群与动脉粥样硬化及中药干预研究进展

肠道菌群与动脉粥样硬化及中药干预研究进展

         

摘要

Atherosclerosis is the pathological basis of many kinds of cardiovascular and cerebrovascular diseases. With the deepening understanding of the relationship between the alteration of gut microbiota and the parenteral diseases, the connection between the alteration of gut microbiota and arteriosclerosis has been gradually revealed. The new idea of treating atherosclerosis through regulating gut microbiota has been explored. This review aims to explain the relationship between the alteration of gut microbiota and atherosclerosis, as well as its risk factors. Meanwhile, the effect and mechanism of Chinese medicine in anti-atherosclerosis through regulating gut microbiota are introduced in this article.%动脉粥样硬化是多种心脑血管疾病的病理基础,目前肠道菌群失调与动脉硬化的相关研究成为热点,以调节肠道菌群为靶点治疗动脉粥样硬化研究逐渐深入.本文就肠道菌群失调与动脉粥样硬化及其危险因素之间的关系、肠道菌群影响动脉粥样硬化的相关机制、肠道菌群失调与动脉粥样硬化危险因素的关系,以及中药有效成分、单味中药或复方对动脉粥样硬化患者肠道菌群紊乱的调节作用进行综述,以期为中药抗动脉粥样硬化研究提供新的思路.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号